<DOC>
	<DOCNO>NCT01072240</DOCNO>
	<brief_summary>This observational study monitor register infusion-related adverse event handle patient chronic lymphocytic leukemia treatment MabThera ( rituximab ) . Data collect patient receive intravenous MabThera dose 375mg/m2 cycle 1 500mg/m2 subsequent cycle treatment visit 6 month . Target sample size 100 patient .</brief_summary>
	<brief_title>An Observational Study Infusion-related Adverse Events Administration MabThera ( Rituximab ) Patients With Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>adult patient , &gt; /= 18 year age chronic lymphocytic leukemia treat rituximab ( MabThera ) rituximab ( MabThera ) dosage 375 mg/m2 cycle 1 , 500 mg/m2 subsequent cycle inform consent data collection participation interventional clinical study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>